专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US06610691B1 Carboxylic acid derivatives, their production and use 失效
标题翻译：羧酸衍生物，其生产和使用
公开(公告)号：US06610691B1
公开(公告)日：2003-08-26
申请号：US09155946
申请日：1998-10-08
申请人： Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Heinz Hillen , Liliane Unger , Bernd Elger
发明人： Hartmut Riechers , Dagmar Klinge , Wilhelm Amberg , Andreas Kling , Heinz Hillen , Liliane Unger , Bernd Elger
IPC分类号： C07D23952
CPC分类号： C07D239/46
摘要： The invention relates to carboxylic acid derivatives of the formula where the radicals have the meanings defined in the description, to the preparation of these compounds and to their use as drugs.
摘要翻译：本发明涉及式（I）的羧酸衍生物，其中自由基具有在描述中定义的含义，这些化合物的制备及其作为药物的用途。

42. 发明授权

US06583166B1 Triazole compounds with dopamine-D3-receptor affinity 有权
标题翻译：具有多巴胺D3受体亲和力的三唑化合物
公开(公告)号：US06583166B1
公开(公告)日：2003-06-24
申请号：US09889163
申请日：2001-07-16
申请人： Dorothea Starck , Hans-Jörg Treiber , Liliane Unger , Barbara Neumann-Schultz , Kai Blumbach , Dietmar Schöbel
发明人： Dorothea Starck , Hans-Jörg Treiber , Liliane Unger , Barbara Neumann-Schultz , Kai Blumbach , Dietmar Schöbel
IPC分类号： C07D40306
CPC分类号： C07D401/04 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14 , C07D491/04
摘要： The invention relates to triazole compounds of formula (I), in which R1, R2, A and B have the meanings given in the description. The compounds provided for in the invention have a high affinity for the dopamine-D3-receptor and can therefore be used for the treatment of diseases which respond to the influence of dopamine-D3-ligands.
摘要翻译：本发明涉及式（I）的三唑化合物，其中R1，R2，A和B具有说明书中给出的含义。本发明中提供的化合物对多巴胺-D3-受体具有高亲和力，因此可用于治疗响应于多巴胺-D3-配体的影响的疾病。

43. 发明授权

US06579892B1 Triazole compounds with dopamine-D3-receptor affinity 有权
标题翻译：具有多巴胺D3受体亲和力的三唑化合物
公开(公告)号：US06579892B1
公开(公告)日：2003-06-17
申请号：US09889156
申请日：2001-07-11
申请人： Dorothea Starck , Hans-Jörg Treiber , Liliane Unger , Barbara Neumann-Schultz , Kai Blumbach , Dietmar Schöbel
发明人： Dorothea Starck , Hans-Jörg Treiber , Liliane Unger , Barbara Neumann-Schultz , Kai Blumbach , Dietmar Schöbel
IPC分类号： C07D40312
CPC分类号： C07D401/04 , C07D249/12 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D409/04 , C07D409/14 , C07D417/04 , C07D417/14 , C07D491/04
摘要： Triazole compounds of the following formula where R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
摘要翻译：以下化合物的三唑化合物R1，R2，A和B具有描述中给出的含义。根据本发明的化合物对多巴胺D3受体具有高亲和力，因此可用于治疗对多巴胺D3配体的影响作出反应的疾病。

44. 发明授权

US5342853A Method of using nor-verapamil and nor-gallopamil as anti-arteriosclerotics 失效
标题翻译：维诺帕米和诺维霉素作为抗动脉硬化的方法
公开(公告)号：US5342853A
公开(公告)日：1994-08-30
申请号：US784426
申请日：1991-11-12
申请人： Claus D. Mueller , Liliane Unger
发明人： Claus D. Mueller , Liliane Unger
IPC分类号： A61K31/275 , A61K31/277 , A61P9/10 , C07C255/44
CPC分类号： A61K31/275 , Y10S514/824
摘要： The use of nor-verapamil and nor-gallopamil and the salts thereof with physiologically tolerated acids is disclosed for the preparation of drugs with antiarteriosclerotic properties.
摘要翻译：公开了用于制备具有抗动脉粥样硬化性质的药物的维拉帕米和诺瓦帕米及其盐与生理上耐受的酸的用途。

45. 发明授权

US4945114A Therapeutic agents containing enantiomers of propafenone 失效
标题翻译：含有普罗帕酮对映异构体的治疗剂
公开(公告)号：US4945114A
公开(公告)日：1990-07-31
申请号：US225756
申请日：1988-07-29
申请人： Albrecht Franke, deceased , Rainer Schlecker , Josef Gries , Gerda Von Philipsborn , Liliane Unger
发明人： Albrecht Franke, deceased , Rainer Schlecker , Josef Gries , Gerda Von Philipsborn , Liliane Unger
IPC分类号： A61K31/135 , A61P9/06 , A61P25/02
CPC分类号： A61K31/135 , Y10S514/821
摘要： Therapeutic agents containing enantiomers of propafenone, the preparation of the said agents and their use for certain groups of patients.
摘要翻译：含有普罗帕酮的对映异构体的治疗剂，所述药剂的制备及其对某些患者组的用途。

46. 发明授权

US08791148B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use 有权
标题翻译：取代的苯并咪唑酮衍生物，包含它们的药物及其用途
公开(公告)号：US08791148B2
公开(公告)日：2014-07-29
申请号：US13302194
申请日：2011-11-22
申请人： Torsten Arndt , Thorsten Oost , Wilfried Lubisch , Wilfried Homberger , Liliane Unger , Juliana Ruiz Caro , Alfred Hahn
发明人： Torsten Arndt , Thorsten Oost , Wilfried Lubisch , Wilfried Homberger , Liliane Unger , Juliana Ruiz Caro , Wolfgang Wernet
IPC分类号： A61K31/4184 , C07D235/26
CPC分类号： A61K31/4184 , C07D235/26
摘要： The present invention relates to novel benzimidazolone derivatives of the general formula (I) in which the substituents R1, R2, R3, A1, A2, and B are as defined in claim 1, medicaments comprising these, and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent diseases.
摘要翻译：本发明涉及通式（I）的新型苯并咪唑酮衍生物，其中取代基R 1，R 2，R 3，A 1，A 2和B如权利要求1中所定义，其组合物及其用于预防和 /或加压素依赖性疾病的治疗。

47. 发明授权

US08486984B2 Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 失效
标题翻译：适用于治疗对多巴胺D3受体调节作出反应的疾病的氨基甲基取代的二环芳族化合物
公开(公告)号：US08486984B2
公开(公告)日：2013-07-16
申请号：US11665287
申请日：2005-10-14
申请人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
发明人： Karla Drescher , Andreas Haupt , Liliane Unger , Sean C. Turner , Wilfried Braje , Roland Grandel
IPC分类号： A61K31/404 , A61K31/4184 , C07D209/14 , C07D235/14
CPC分类号： C07D471/04 , C07D209/14 , C07D209/62 , C07D235/14
摘要： The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
摘要翻译：本发明涉及式I的氨基甲基取代的双环芳族化合物。本发明还涉及式I化合物或其药学上可接受的盐在制备用于治疗易受治疗的医学疾病的药物组合物中的用途与多巴胺D3受体配体。

48. 发明授权

US08486931B2 Substituted oxindole compounds 有权
标题翻译：取代的羟吲哚化合物
公开(公告)号：US08486931B2
公开(公告)日：2013-07-16
申请号：US12529542
申请日：2008-02-29
申请人： Herve Genesle , Thorsten Oost , Charles W. Hutchins , Liliane Unger , Wilfried Hornberger , Wilfried Lubisch , Astrid Netz , Alfred Hahn
发明人： Herve Genesle , Thorsten Oost , Charles W. Hutchins , Liliane Unger , Wilfried Hornberger , Wilfried Lubisch , Astrid Netz , Wolfgang Wernet
IPC分类号： A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/551
CPC分类号： C07D401/14 , C07D401/04 , C07D401/12 , C07D471/08
摘要： The present invention relates to compounds of the general formula (I) in which A, B, R1, R2 and Het have the meaning given in claim 1; Y is a bivalent group of the formula in which D is C1-C3-alkylene, where D may have a substituent R5; R3 is hydrogen, C1-C8-alkyl or together with R4 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, and R4 is hydrogen, C1-C8-alkyl or together with R3 is C1-C3-alkylene which may have a radical R5a, or together with R5 is C1-C3-alkylene, where R5 together with R5a, where present, are a bond or C1-C3-alkylene; and where one of the following conditions is satisfied: R3 together with R4 is C1-C3-alkylene which may have a radical R5a; or R3 together with R5 is C1-C3-alkylene; or R4 together with R5 is C1-C3-alkylene where the radical A is different from phenyl when the radical B is phenyl or naphthyl; and medicaments which comprise such compounds and the use thereof for the prophylaxis and/or treatment of vasopressin-dependent and/or oxytocin-dependent diseases.
摘要翻译：本发明涉及通式（I）的化合物，其中A，B，R1，R2和Het具有权利要求1中给出的含义; Y是下式的二价基团，其中D是C 1 -C 3 - 亚烷基，其中D可以具有取代基R 5; R 3是氢，C 1 -C 8烷基或与R 4一起是可以具有基团R 5a的C 1 -C 3亚烷基，或与R 5一起为C 1 -C 3 - 亚烷基，并且R 4是氢，C 1 -C 8 - 烷基或与 R 3是可以具有基团R 5a的C 1 -C 3亚烷基，或与R 5一起为C 1 -C 3 - 亚烷基，其中R 5与存在的R a a为键或C 1 -C 3 - 亚烷基; 并且其中满足以下条件之一：R 3与R 4一起可以具有基团R 5a的C 1 -C 3 - 亚烷基; 或R 3与R 5一起为C 1 -C 3 - 亚烷基; 或R 4与R 5一起为C 1 -C 3 - 亚烷基，其中基团B为苯基或萘基时，基团A不同于苯基; 以及包含这些化合物的药物及其用于预防和/或治疗加压素依赖性和/或催产素依赖性疾病的用途。

49. 发明授权

US08350055B2 Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them 有权
公开(公告)号：US08350055B2
公开(公告)日：2013-01-08
申请号：US12839612
申请日：2010-07-20
申请人： Thorsten Oost , Wilfried Hornberger , Herve Geneste , Daryl Richard Sauer , Wolfgang Wernet , Andrea Hager-Wernet, legal representative , Liliane Unger , Wilfried Lubisch
发明人： Thorsten Oost , Wilfried Hornberger , Herve Geneste , Daryl Richard Sauer , Wolfgang Wernet , Liliane Unger , Wilfried Lubisch
IPC分类号： C07D411/00
CPC分类号： C07D401/14 , C07D401/12 , C07D403/14 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/14 , C07D513/04
摘要： The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6, and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.

50. 发明授权

US08242102B2 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor 有权
标题翻译：喹啉化合物适用于治疗对血清素5-HT6受体调节作用的疾病
公开(公告)号：US08242102B2
公开(公告)日：2012-08-14
申请号：US12532407
申请日：2008-03-23
申请人： Sean Colm Turner , Andreas Haupt , Wilfried Braje , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Alfred Hahn, legal representative , Matthias Mayrer
发明人： Sean Colm Turner , Andreas Haupt , Wilfried Braje , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer
IPC分类号： A61K31/397 , C07D215/00
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to novel quinoline compounds. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R is a moiety of the formula wherein A, R1 to R4 are as defined in the claims and the specification, n is 0, 1 or 2; m is 0, 1, 2 or 3; Ra, Rb are independently selected from the group consisting of halogen, CN, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C(O)Raa, C(O)NRccRbb and NRccRbb; X is CH2, C(O), S, S(O) or S(O)2; which is located in the 3- or 4-position of the quinoline ring; Ar is a radical Ar1, Ar2—Ar3 or Ar2—O—Ar3, wherein Ar1, Ar2 and Ar3 are each independently selected from the group consisting of aryl or hetaryl wherein aryl or hetaryl moieties may be unsubstituted or may carry 1, 2, 3 substituents Rx, wherein and physiologically tolerated acid addition salts and the N-oxides thereof.
摘要翻译：本发明涉及新颖的喹啉化合物。该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。其中R是下式的部分，其中A，R 1至R 4如权利要求和说明书中所定义，n为0,1或2; m为0,1,2或3; R a，R b独立地选自卤素，CN，C 1 -C 4 - 烷基，C 1 -C 4卤代烷基，C 1 -C 4 - 烷氧基，C 1 -C 4卤代烷氧基，C（O）R aa，C（O）NR c R b b 和NRccRbb; X是CH 2，C（O），S，S（O）或S（O）2; 其位于喹啉环的3-或4-位; Ar是Ar1，Ar2-Ar3或Ar2-O-Ar3基团，其中Ar1，Ar2和Ar3各自独立地选自芳基或杂芳基，其中芳基或杂芳基部分可以是未取代的或可以携带1,2,3 取代基Rx，其中和生理上耐受的酸加成盐及其N-氧化物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式